I-Mab (0VY.F)
| Previous Close | 1.6800 |
| Open | 1.6600 |
| Bid | 1.6800 x N/A |
| Ask | 1.7100 x N/A |
| Day's Range | 1.6600 - 1.6600 |
| 52 Week Range | 1.0900 - 3.0400 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 134.535M |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024.
- PR Newswire
I-Mab Announces Closing of the Divestiture of Business Operations in China
I-Mab (the "Company") (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that all conditions precedent to the divestiture transaction previously announced on February 7, 2024 (the "Transaction") have been either satisfied or waived and accordingly, the Transaction has successfully closed.
- PR Newswire
I-Mab Reports Full Year 2023 Financial Results and Business Update
I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the full year ended December 31, 2023, and highlighted recent business updates.
